What You Should Know:
– Innatea technology platform that connects pharma companies (trial sponsors) with community-based trial sites raises $20M in new funding (A2) led by Cathay Innovation with participation from existing investor Obvious Ventures and new investors La Maison and Top Harvest Capital. Inato works with many of the top 30 pharmaceutical companies worldwide to make clinical trials more inclusive.
– The new funding will fuel Inato’s continued product innovation, international growth, and hiring of top talent. Inato will advance its diversity product offering to enable sponsors to strategically meet their diversity goals based on new FDA requirements.
– Inato will also invest in oncology-specific innovation to increase access to care where, despite the number of oncology studies increasing at almost twice the pace of any other therapeutic area, enrollment rates remain startlingly low. Inato will also further define and scale its data model to continue to improve matching reliability between community sites and sponsor trials.